Virologica Sinica

, Volume 30, Issue 5, pp 386–395 | Cite as

Multiple-site mutations of phage Bp7 endolysin improves its activities against target bacteria

Research Article

Abstract

The widespread use of antibiotics has caused serious drug resistance. Bacteria that were once easily treatable are now extremely difficult to treat. Endolysin can be used as an alternative to antibiotics for the treatment of drug-resistant bacteria. To analyze the antibacterial activity of the endolysin of phage Bp7 (Bp7e), a 489-bp DNA fragment of endolysin Bp7e was PCR-amplified from a phage Bp7 genome and cloned, and then a pET28a-Bp7e prokaryotic expression vector was constructed. Two amino acids were mutated (L99A, M102E) to construct pET28a-Bp7Δe, with pET28a-Bp7e as a template. Phylogenetic analysis suggested that BP7e belongs to a T4-like phage endolysin group. Bp7e and its mutant Bp7Δe were expressed in Escherichia coli BL21(DE3) as soluble proteins. They were purified by affinity chromatography, and then their antibacterial activities were analyzed. The results demonstrated that the recombinant proteins Bp7e and Bp7Δe showed obvious antibacterial activity against Micrococcus lysodeikticus but no activity against Staphylococcus aureus. In the presence of malic acid, Bp7e and Bp7Δe exhibited an effect on most E. coli strains which could be lysed by phage Bp7, but no effect on Salmonella paratyphi or Pseudomonas aeruginosa. Moreover, Bp7Δe with double-site mutations showed stronger antibacterial activity and a broader lysis range than Bp7e.

Keywords

bacteriophage Bp7 endolysin (Bp7e) Bp7 endolysin mutant (Bp7Δe) prokaryotic expression antibacterial activity 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Baase WA, Liu L, Tronrud DE, Matthews BW. 2010. Lessons from the lysozyme of phage T4. Protein Science, 19: 631–641.PubMedCentralCrossRefPubMedGoogle Scholar
  2. Borysowski J, Weber-Dabrowska B, Gorski A. 2006. Bacteriophage endolysins as a novel class of antibacterial agents. Exp Biol Med, 231: 366–377.Google Scholar
  3. Briers Y, Walmagh M, Lavigne R. 2011. Use of bacteriophage endolysin EL188 and outer membrane permeabilizers against Pseudomonas aeruginosa. J Appl Microbiol, 110: 778–785.CrossRefPubMedGoogle Scholar
  4. Burrowes B, Harper DR, Anderson J, McConville M, Enright MC. 2011. Bacteriophage therapy: potential uses in the control of antibiotic-resistant pathogens. Expert Rev Anti Infect Ther, 9: 775–785.CrossRefPubMedGoogle Scholar
  5. Dupont HL, Jiang ZD, Belkind-Gerson J, Okhuysen PC, Ericsson CD, Ke S, Huang DB, Dupont MW, Adachi JA, De La Cabada FJ, Taylor DN, Jaini S, Martinez SF. 2007. Treatment of travelers' diarrhea: randomized trial comparing rifaximin, rifaximin plus loperamide, and loperamide alone. Clin Gastroenterol Hepatol, 5: 451–456.CrossRefPubMedGoogle Scholar
  6. Endersen L, Guinane CM, Johnston C, Neve H, Coffey A, Ross RP, McAuliffe O, O'Mahony J. 2015. Genome analysis of Cronobacter phage vB_CsaP_Ss1 reveals an endolysin with potential for biocontrol of Gram-negative bacterial pathogens. J Gen Virol, 96: 463–477.CrossRefPubMedGoogle Scholar
  7. Eriksson AE, Baase WA, Wozniak JA, Matthews BW. 1992. A cavity-containing mutant of T4 lysozyme is stabilized by buried benzene. Nature, 355: 371–373.CrossRefPubMedGoogle Scholar
  8. Fischetti VA. 2008. Bacteriophage lysins as effective antibacterials. Curr Opin Microbiol, 11: 393–400.PubMedCentralCrossRefPubMedGoogle Scholar
  9. Fischetti VA. 2010. Bacteriophage endolysins: a novel anti-infective to control Gram-positive pathogens. Int J Med Microbiol, 300: 357–362.PubMedCentralCrossRefPubMedGoogle Scholar
  10. Legotsky SA, Vlasova KY, Priyma AD, Shneider MM, Pugachev VG, Totmenina OD, Kabanov AV, Miroshnikov KA, Klyachko NL. 2014. Peptidoglycan degrading activity of the broad-range Salmonella bacteriophage S-394 recombinant endolysin. Biochimie, 107: 293–299.CrossRefPubMedGoogle Scholar
  11. Li H, Ma ML, Xie HJ, Kong J. 2012. Biosafety evaluation of bacteriophages for treatment of diarrhea due to intestinal pathogen Escherichia coli 3-2 infection of chickens. World J Microbiol Biotechnol, 28: 1–6.CrossRefPubMedGoogle Scholar
  12. Lim J A, Shin H, Heu S, Ryu S. 2014. Exogenous lytic activity of SPN9CC endolysin against gram-negative bacteria. J Microbiol Biotechnol, 24: 803–811.PubMedGoogle Scholar
  13. Liu L, Baase WA, Michael MM, Matthews BW. 2009. Use of stabilizing mutations to engineer a charged group within a ligandbinding hydrophobic cavity in T4 lysozyme. Biochemistry, 48: 8842–8851.CrossRefPubMedGoogle Scholar
  14. Liu L, Quillin ML, Matthews BW. 2008. Use of experimental crystallographic phases to examine the hydration of polar and nonpolar cavities in T4 lysozyme. Proc Natl Acad Sci USA, 105: 14406–14411.PubMedCentralCrossRefPubMedGoogle Scholar
  15. López CJ, Yang Z, Altenbach C, Hubbell WL. 2013. Conformational selection and adaptation to ligand binding in T4 lysozyme cavity mutants. Proc Natl Acad Sci U S A, 110: E4306–E4315.PubMedCentralCrossRefPubMedGoogle Scholar
  16. Lukacik P, Barnard TJ, Hinnebusch BJ, Buchanan SK. 2013. Specific targeting and killing of Gram-negative pathogens with an engineered phage lytic enzyme. Virulence, 4: 90–91.PubMedCentralCrossRefPubMedGoogle Scholar
  17. Nelson DC, Schmelcher M, Rodriguez-Rubio L, Klumpp J, Pritchard DG, Dong S, Donovan DM. 2012. Endolysins as antimicrobials. Virus Res, 83: 299–365.CrossRefGoogle Scholar
  18. Oliveira H, Melo LD, Santos SB, Nóbrega FL, Ferreira EC, Cerca N, Azeredo J, Kluskens LD. 2013. Molecular aspects and comparative genomics of bacteriophage endolysins. J Virol, 87: 4558–4570.PubMedCentralCrossRefPubMedGoogle Scholar
  19. Oliveira H, Thiagarajan V, Walmagh M, Sillankorva S, Lavigne R, Neves-Petersen MT, Kluskens LD, Azeredo J. 2014. A Thermostable Salmonella Phage Endolysin, Lys68, with Broad Bactericidal Properties against Gram-Negative Pathogens in Presence of Weak Acids. PLoS One, 9: e108376.PubMedCentralCrossRefPubMedGoogle Scholar
  20. Olsen RH, Frantzen C, Christensen H, Bisgaard M. 2012. An investigation on first-week mortality in layers. Avian Dis, 56: 51–57.CrossRefPubMedGoogle Scholar
  21. Trudil D. 2015. Phage lytic enzymes: a history. Virol Sin, 30: 26–32.CrossRefPubMedGoogle Scholar
  22. Xu J, Baase WA, Baldwin E, Matthews BW. 1998. The response of T4 lysozyme to large-to-small substitutions within the core and its relation to the hydrophobic effect. Protein Science, 7: 158–177.PubMedCentralCrossRefPubMedGoogle Scholar
  23. Xu Y, Liu Y, Liu Y, Pei J, Yao S, Cheng C. 2015. Bacteriophage therapy against Enterobacteriaceae. Virol Sin, 30: 11–8.CrossRefPubMedGoogle Scholar
  24. Zhang C, Li W, Liu W, Zou L, Yan C, Lu K, Ren H. 2013. T4-like phage Bp7, a potential antimicrobial agent for controlling drugresistant Escherichia coli in chickens. Appl Environ Microbiol, 79: 5559–5565.PubMedCentralCrossRefPubMedGoogle Scholar
  25. Zhang T, Wang CG, Lv JC, Wang RS, Zhong XH. 2012. Survey on tetracycline resistance and antibiotic-resistant genotype of avian Escherichia coli in North China. Poult Sci, 91: 2774–2777.CrossRefPubMedGoogle Scholar

Copyright information

© Wuhan Institute of Virology, CAS and Springer-Verlag Berlin Heidelberg 2015

Authors and Affiliations

  • Can Zhang
    • 1
  • Yuanchao Wang
    • 1
  • Huzhi Sun
    • 1
  • Huiying Ren
    • 1
  1. 1.College of Animal Husbandry and Veterinary MedicineQingdao Agricultural UniversityQingdaoChina

Personalised recommendations